Document Detail

Inhibition of cardiac baroreflex sensitivity after central dopaminergic stimulation.
MedLine Citation:
PMID:  9673440     Owner:  NLM     Status:  MEDLINE    
1. Stimulation of the mesolimbic dopamine system, by micro-injection of the substance P analogue [pGlu5,MePhe8,Sar9] substance P (DiMe-C7) into the ventral tegmental area induced a prolonged increase in blood pressure and circulating levels of vasopressin. 2. In the present study, this treatment produced a significant decrease of cardiac baroreflex sensitivity in conscious rats. After pretreatment with the dopamine receptor antagonist raclopride, central stimulation failed to produce any changes in baroreflex parameters. 3. The central dopamine-mediated decrease in baroreflex sensitivity may be involved in functionally potentiating the circulatory actions of vasopressin.
M van den Buuse; D P Wilks; J L Cornish
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental pharmacology & physiology     Volume:  25     ISSN:  0305-1870     ISO Abbreviation:  Clin. Exp. Pharmacol. Physiol.     Publication Date:    1998 Jul-Aug
Date Detail:
Created Date:  1998-10-09     Completed Date:  1998-10-09     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0425076     Medline TA:  Clin Exp Pharmacol Physiol     Country:  AUSTRALIA    
Other Details:
Languages:  eng     Pagination:  624-6     Citation Subset:  IM    
Baker Medical Research Institute, Prahran, Victoria, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Baroreflex / physiology*
Dopamine / physiology*
Dopamine Agonists / administration & dosage,  pharmacology
Dopamine Antagonists / pharmacology
Heart / physiology*
Heart Rate / drug effects
Peptide Fragments / administration & dosage,  pharmacology
Pyrrolidonecarboxylic Acid / analogs & derivatives
Rats, Sprague-Dawley
Salicylamides / pharmacology
Substance P / administration & dosage,  analogs & derivatives,  pharmacology
Vasopressins / blood
Ventral Tegmental Area
Reg. No./Substance:
0/Dopamine Agonists; 0/Dopamine Antagonists; 0/Peptide Fragments; 0/Salicylamides; 11000-17-2/Vasopressins; 33507-63-0/Substance P; 77128-69-9/substance P (5-11), pGlu(5)-MePhe(8)-MeGly(9)-; 84225-95-6/Raclopride; 98-79-3/Pyrrolidonecarboxylic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pituitary-adrenal responses to combined oral D-fenfluramine and intravenous naloxone in humans.
Next Document:  A linkage and cross-sectional study of hypertension and obesity using a poly (A) Alu-repeat polymorp...